Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia
Alemtuzumab, under the brand name Campath, was pulled from the leukaemia market by Sanofi in 2012.
Alemtuzumab, under the brand name Campath, was pulled from the leukaemia market by Sanofi in 2012.
What's Your Reaction?
